Eyenovia (EYEN)
(Delayed Data from NSDQ)
$1.07 USD
-0.10 (-8.55%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $1.08 +0.01 (0.93%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Eyenovia, Inc. [EYEN]
Reports for Purchase
Showing records 21 - 40 ( 84 total )
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
4Q20, VISION-1 Results 2Q21, MydCombi Approval 4Q21, Funded to Mid-2022
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology: Invitation: Virtual 33rd Annual Roth Conference (March 15-17)
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
New Drug Application Submitted for MydCombi; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 Presbyopia Trial Starts Patient Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
3Q20: MicroLine Phase 3 Start Imminent, Mydcombi NDA Filing by YE20
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
MicroPine Out-Licensed; Financing Complete; Reiterate Buy: Lowering PT to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Bausch Health Licenses MicroPine in U.S. and Canada - PT to $11 from $14
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
2Q20 Financial Results Reported; Reiterate Buy: Raising PT to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
2Q20: COVID-19 Delays Lightening Up, Inks Asian MicroLine - MicroPine Deal
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
MicroPine Phase 3 Trial Resumes Enrollment of Myopia Patients; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
1Q20 Financial Results; Trial Enrollment Delayed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
1Q20: MicroStat NDA by YE20; COVID-19 Slows Phase 3s; PT to $14 from $16
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eyenovia, Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 MicroLine and MicroPine Trials Subject to COVID-19 Related Delays
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J